See more : Zhongyu Energy Holdings Limited (3633.HK) Income Statement Analysis – Financial Results
Complete financial analysis of AVEO Pharmaceuticals, Inc. (AVEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AVEO Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Welltend Technology Corporation (3021.TW) Income Statement Analysis – Financial Results
- Compagnie Plastic Omnium SE (POM.PA) Income Statement Analysis – Financial Results
- Real Good Food plc (RGD.L) Income Statement Analysis – Financial Results
- Nampak Limited (NPKLY) Income Statement Analysis – Financial Results
- Healios K.K. (4593.T) Income Statement Analysis – Financial Results
AVEO Pharmaceuticals, Inc. (AVEO)
About AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.87M | 6.02M | 28.80M | 5.41M | 7.58M | 2.52M | 19.02M | 18.12M | 1.29M | 19.29M | 164.85M | 44.68M | 20.72M | 19.66M | 11.03M |
| Cost of Revenue | 4.74M | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 34.14M | 4.77M | 28.80M | 5.41M | 7.58M | 2.52M | 19.02M | 18.12M | 1.29M | 19.29M | 164.85M | 44.68M | 20.72M | 19.66M | 11.03M |
| Gross Profit Ratio | 87.81% | 79.32% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 26.30M | 22.68M | 17.96M | 20.65M | 25.18M | 23.70M | 12.88M | 38.25M | 68.47M | 91.36M | 101.74M | 86.35M | 51.79M | 41.82M | 29.25M |
| General & Administrative | 0.00 | 22.22M | 11.21M | 10.78M | 9.14M | 8.21M | 14.22M | 18.59M | 28.71M | 36.93M | 29.17M | 14.76M | 10.12M | 9.16M | 6.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 60.81M | 22.22M | 11.21M | 10.78M | 9.14M | 8.21M | 14.22M | 18.59M | 28.71M | 36.93M | 29.17M | 14.76M | 10.12M | 9.16M | 6.50M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.36M | 11.73M | 8.02M | 2.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 87.11M | 44.90M | 29.17M | 31.43M | 34.32M | 31.91M | 27.09M | 56.84M | 97.18M | 128.29M | 130.90M | 101.11M | 61.91M | 50.99M | 35.75M |
| Cost & Expenses | 91.85M | 44.90M | 29.17M | 31.43M | 34.32M | 31.91M | 27.09M | 56.84M | 97.18M | 128.29M | 130.90M | 101.11M | 61.91M | 50.99M | 35.75M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.00K | 32.00K | 125.00K | 497.00K | 527.00K | 126.00K | 144.26K | 1.17M | 2.17M |
| Interest Expense | -4.05M | 1.61M | 1.82M | 2.19M | 2.37M | 1.95M | 2.31M | 2.39M | 3.13M | 3.50M | 3.84M | 3.39M | 2.81M | 2.09M | 2.44M |
| Depreciation & Amortization | -7.83M | 21.00K | 11.58M | 22.22M | -33.74M | 30.00K | 9.57M | 6.22M | 3.78M | 2.51M | 1.65M | 1.35M | 1.29M | 1.32M | 1.33M |
| EBITDA | -57.39M | -33.96M | 11.20M | -3.14M | -62.55M | -24.81M | -3.13M | -44.13M | -100.13M | -108.38M | 36.14M | -54.05M | -40.09M | -29.07M | -21.21M |
| EBITDA Ratio | -147.62% | -564.18% | 38.91% | -58.01% | -825.32% | -986.36% | -16.44% | -243.51% | -7,743.77% | -561.98% | 21.92% | -120.97% | -193.52% | -147.84% | -192.22% |
| Operating Income | -49.55M | -38.88M | -374.00K | -25.36M | -28.81M | -29.39M | -12.43M | -50.45M | -103.90M | -111.64M | 33.95M | -56.43M | -41.19M | -31.33M | -24.72M |
| Operating Income Ratio | -127.47% | -645.90% | -1.30% | -468.79% | -380.14% | -1,168.71% | -65.32% | -278.37% | -8,035.89% | -578.85% | 20.59% | -126.28% | -198.83% | -159.33% | -223.99% |
| Total Other Income/Expenses | -3.79M | 3.29M | 9.76M | 20.03M | -36.11M | 2.61M | -2.58M | -2.29M | -3.13M | -2.76M | -3.30M | -2.36M | -3.00M | -1.15M | -266.03K |
| Income Before Tax | -53.34M | -35.58M | 9.39M | -5.33M | -64.92M | -26.79M | -15.00M | -52.74M | -107.03M | -114.39M | 30.65M | -58.79M | -44.19M | -32.47M | -24.98M |
| Income Before Tax Ratio | -137.22% | -591.19% | 32.60% | -98.52% | -856.63% | -1,065.05% | -78.85% | -291.01% | -8,277.57% | -593.15% | 18.59% | -131.57% | -213.30% | -165.17% | -226.40% |
| Income Tax Expense | 7.83M | 4.90M | 0.00 | 0.00 | 101.00K | 101.00K | -268.00K | 98.00K | 2.00K | 744.00K | 537.00K | 1.03M | -100.06K | 937.81K | 2.17M |
| Net Income | -61.18M | -35.58M | 9.39M | -5.33M | -65.03M | -26.89M | -15.00M | -52.74M | -107.03M | -114.39M | 30.65M | -58.79M | -44.09M | -32.47M | -24.98M |
| Net Income Ratio | -157.37% | -591.19% | 32.60% | -98.52% | -857.96% | -1,069.07% | -78.85% | -291.01% | -8,277.57% | -593.15% | 18.59% | -131.57% | -212.82% | -165.17% | -226.40% |
| EPS | -2.86 | -1.66 | 0.61 | -0.41 | -6.14 | -3.88 | -2.69 | -10.09 | -21.02 | -26.37 | 7.72 | -22.98 | -22.31 | -202.07 | -155.46 |
| EPS Diluted | -2.86 | -1.66 | 0.61 | -0.41 | -6.14 | -3.88 | -2.69 | -10.09 | -21.02 | -26.37 | 7.39 | -22.98 | -22.31 | -202.07 | -155.46 |
| Weighted Avg Shares Out | 21.40M | 21.40M | 15.38M | 13.07M | 10.59M | 6.93M | 5.57M | 5.23M | 5.09M | 4.34M | 3.97M | 2.56M | 1.98M | 160.70K | 160.70K |
| Weighted Avg Shares Out (Dil) | 21.40M | 21.40M | 15.38M | 13.07M | 10.59M | 6.93M | 5.57M | 5.23M | 5.09M | 4.34M | 4.15M | 2.56M | 1.98M | 160.70K | 160.70K |
AVEO (AVEO) is on the Move, Here's Why the Trend Could be Sustainable
Buy These 3 Top Breakout Stocks Now for Superb Returns
5 Top Stocks to Buy on New Analysts' Coverage
AVEO Oncology Announces Participation at Investor Conferences in September
Here's Why AVEO Pharmaceuticals (AVEO) is a Great Momentum Stock to Buy
What Makes AVEO (AVEO) a Good Fit for "Trend Investing"
A Current Assessment On AVEO Pharmaceuticals
Has AVEO Pharmaceuticals (AVEO) Outpaced Other Medical Stocks This Year?
Recent Price Trend in AVEO (AVEO) is Your Friend, Here's Why
AVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q2 2022 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports